×
Endo Net Current Debt 2023-2025 | NDOI
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Endo net current debt from 2023 to 2025. Net current debt can be defined as the net amount of debt repaid and issued with short-term maturities.
View More
Endo Net Current Debt 2023-2025 | NDOI
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Endo net current debt from 2023 to 2025. Net current debt can be defined as the net amount of debt repaid and issued with short-term maturities.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$81.3B
Zoetis (ZTS)
$67.7B
Daiichi Sankyo, - (DSNKY)
$46.4B
Takeda Pharmaceutical (TAK)
$46.1B
BeOne Medicines - (ONC)
$31.9B
Sandoz Group AG (SDZNY)
$26.1B
Summit Therapeutics (SMMT)
$21.3B
Merck (MKKGY)
$17.2B
Shionogi (SGIOY)
$14.6B
United Therapeutics (UTHR)
$13.7B
Neurocrine Biosciences (NBIX)
$13.1B
Orion OYJ (ORINY)
$11.7B
IPSEN (IPSEY)
$10.9B
Stevanato Group S.p.A (STVN)
$8B
Corcept Therapeutics (CORT)
$7.2B
Grifols, S.A (GRFS)
$6.9B
Ionis Pharmaceuticals (IONS)
$6.7B
Madrigal Pharmaceuticals (MDGL)
$6.6B
Hikma Pharmaceuticals Plc (HKMPF)
$6.2B
Ono Pharmaceutical (OPHLF)
$5.2B
Soleno Therapeutics (SLNO)
$4.4B
Hypermarcas (HYPMY)
$2.9B
Crinetics Pharmaceuticals (CRNX)
$2.9B
NewAmsterdam Pharma (NAMS)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.5B
Centessa Pharmaceuticals (CNTA)
$2.1B
Ocular Therapeutix (OCUL)
$1.9B
BioCryst Pharmaceuticals (BCRX)
$1.8B
ARS Pharmaceuticals (SPRY)
$1.8B